Corgentech Clinches Bristol-Myers Squibb Alliance
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 42 (Table of Contents)
Published: 3 Dec-2003
DOI: 10.3833/pdr.v2003.i42.844 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Corgentech collaborates with Bristol-Myers Squibb to jointly develop and commercialize Corgentech’s E2F Decoy (edifoligide sodium) used to prevent vein graft failure following coronary and peripheral artery bypass graft surgery...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS